Oncosurgery

Radio active Iodine in Thyroid Cancer

by

Q) Which of the following is not true about Radioactive Iodine (RAI) use in thyroid cancer? (Thyroid onco) 

a) Screening with RAI  is less sensitive than Thyroglobulin estimation in most differentiated thyroid cancers for detecting metastasis

b) Metastatic differentiated thyroid carcinoma can be detected by  131I in about 50% of patients

c) Current guidelines s recommend RAI after total thyroidectomy only for patients with known distant metastases

d) Hurthle cell cancer des not take up RAI

 

Bladder Cancer

by

Q) What is the most suitable treatment option for non muscle-invasive bladder cancer with the risk of recurrences?

A)Cystectomy

B)Intravesical chemotherapy

C)Transurethral resection and adjuvant intravesical chemotherapy

D)Palliative therapy

Answer-C(Schwartz-1654)

Patients with non–muscle-invasive bladder cancer (confined to the bladder mucosa or submucosa) can be managed with transurethral resection alone and adjuvant intravesical (instilled into the bladder) chemotherapy/immunotherapy.

The use of these intravesical agents is critical since patients with non–muscle-invasive bladder cancer are at risk for tumour recurrence and progression.

 

Uro Onco MCQS

Bevacizumab

by
Bevacizumab MCQ
Q) Not true about use of Bevacizumab
a) It is a humanized monoclonal antibody against VEGF A
b) Bevacizumab is a first-line treatment in metastatic nonsquamous non-small cell lung cancer.
c) Bevacizumab is a first-line or second-line therapy for metastatic colorectal cancer
d) Its major advantage is that it has replaced combination chemotherapy
Correct Answer: d) Its major advantage is that it has replaced combination chemotherapy
Explanation: a) True – Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis. b) True – Bevacizumab is used as first-line treatment in combination with chemotherapy for metastatic nonsquamous non-small cell lung cancer (NSCLC). c) True – Bevacizumab is used as first-line and second-line therapy in combination with chemotherapy for metastatic colorectal cancer. d) Not true – Bevacizumab is not a replacement for combination chemotherapy. Instead, it is used in combination with standard chemotherapy regimens to improve efficacy. It is not used as a monotherapy in most settings.